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1. Introduction
Myocarditis is a clinical syndrome characterized by inflammation of myocardium and
caused by a myriad of etiologies including infectious, autoimmune, myocardial toxins, hy‐
persensitivity reactions and physical agents. Human myocarditis is most frequently caused
by viral infection. Ongoing viral infection, myocardial injury, and adverse remodeling can
lead to persistent ventricular dysfunction and dilated cardiomyopathy.
The clinical manifestations are highly variable, ranging from asymptomatic electrocardio‐
graphic or echocardiographic abnormalities to acute myocardial infarction-like syndrome,
overt congestive heart failure, cardiogenic shock, and death. Myocarditis is occasionally the
unrecognized culprit in cases of sudden cardiac death. Autopsy series have reported that rates
of myocarditis much higher than expected, with overt clinical manifestation from different
etiological agents. Postmortem data have implicated myocarditis in 8.6 % to 12 % of sudden
cardiac death of young adults [1,2]. Furthermore, it has been identified as a cause of dilated car‐
diomyopathy in 9 % of cases in a large prospective series [3]. The clinical history in patients pre‐
sented with myocarditis remains essential to encompass a wide variety of etiologies, many of
which are infectious [4]. In the past 10 years, however, viruses, including adenovirus, parvovi‐
rus B19, hepatitis C, and herpes virus 6, have emerged as significant pathogens [5]. The geo‐
graphical distribution can be of relevance for some forms of myocarditis. In selected countries,
Chagas disease, Lyme myocarditis, acute rheumatic fever, and disorders associated with ad‐
vanced human immune deficiency virus infection are significant causes. Other less frequent
clinicopathological variants in the etiological spectrum are systemic disorders like giant cell
myocarditis, cardiac sarcoidosis and eosinophilic myocarditis. Additionally, drugs, vaccina‐
tions, toxins, physical agents like radiation, heat stroke and hypothermia can be the key point
for some rare clinical diagnoses. Although histological findings remain the gold standard for
establishing the diagnosis of myocarditis, low risk patients are often given a presumptive diag‐
nosis if imaging studies and a compatible clinical scenario suggest new-onset cardiomyopathy.
© 2013 Al-Aqeedi; licensee InTech. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Clinicopathological forms
The changing diagnostic criteria, multifaceted classifications, and varying patterns of infec‐
tious disease yielded great deal of confusion over the past two decades. The morphologic crite‐
ria for the diagnosis of myocarditis by means of endomyocardial biopsy was proposed by the
Dallas criteria in 1986, which defined myocarditis as a process characterized by the presence of
an inflammatory cell infiltration of the myocardium with necrosis and/or degeneration of myo‐
cytes that is not typical of the myocardial injury of ischemic heart disease. The inflammatory
cells are typically lymphocytic but may also include eosinophilic, neutrophilic, giant cells,
granulomatous, or mixed cellularity infiltration. The amount of inflammation and its distribu‐
tion may be mild, moderate, or severe, and focal, confluent, or diffuse, respectively. A retro‐
spective study of 112 consecutive patients with biopsy-confirmed myocarditis demonstrated,
55 % lymphocytic; 22 % borderline (inflammatory cellular infiltrate with no evidence of myo‐
cyte necrosis); 10 % granulomatous; 6 % giant cell and 6 % eosinophilic form of myocarditis [6].
Viral etiology of myocarditis is thought to be the primary cause in most cases. However, a di‐
rect causative relationship remains less well established in many clinical occasions. The majori‐
ty of these cases are classified as lymphocytic myocarditis.
The Dallas criteria are considered the first attempt to develop standardized histopathologi‐
cal description of biopsy samples from patients presented with myocarditis [7]. However,
histopathology alone can be inadequate to identify the presence of active myocarditis. Some
clinicians feel that the definition is too narrow, owing to the limitation by variable interpre‐
tation, lack of clinical prognostic values, and low sensitivity [8]. A combination of histopa‐
thological characteristics and clinical criteria has been proposed in 1991 [9] as an alternative
scheme to be utilized in the diagnosis of myocarditis. Histologic evidence of myocarditis
was demonstrated in 35 of 348 patients submitted to endomyocardial biopsy over 5 years.
Analysis of the histologic findings and clinical course of these patients resulted in a clinico‐
pathological classification of myocarditis in which four clinical subgroups are identified.
The first form of myocarditis is fulminant myocarditis, which is a less frequent form of presen‐
tation. The patients present with acute heart failure and cardiogenic shock up to two weeks
after a distinct viral prodromal episode. They have severe cardiovascular compromise and
may require mechanical circulatory support. Multiple foci of active myocarditis are typically
found. The histopathological finding does not match the clinical phenotypic severity. Ven‐
tricular dysfunction often normalizes if patients survive the acute illness [10]. In one series,
14 of 147 patients (10.2 %) with clinical myocarditis presented in a fulminant fashion, with
the triad of hemodynamic compromise, rapid onset of symptoms (usually within 2 weeks),
and fever [10]. On follow up, 93 % of the original cohorts were alive and transplant free 11
years following initial biopsy, compared with only 45 % in those with more classic forms of
acute myocarditis. The second form of myocarditis is acute myocarditis, which describes pa‐
tients who classically presented with a less distinct onset of illness with nonspecific symp‐
toms related to the heart. Viral prodromal episode occurs between 20 and 80 % of the cases,
which can be missed by the patient, and thus cannot be relied upon for diagnosis. They
present with an established ventricular dysfunction and may respond to immunosuppres‐
sive therapy or their condition may progress to dilated cardiomyopathy. In a series of 245
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patients with clinically suspected myocarditis, the most common symptoms include fatigue
(82 %); dyspnea on exertion (81 %); arrhythmias (55 %, both supraventricular and ventricu‐
lar); palpitations (49 %); and chest pain at rest (26 %), [11]. The presentation can mimic acute
coronary syndromes in view of troponin release, ST segment elevation on electrocardio‐
gram, and segmental wall motion abnormalities on echocardiogram. The third form of myo‐
carditis is chronic active myocarditis, which describes the majority of older adult patients with
myocarditis. They are also presents with a less distinct onset of illness, often insidious, with
symptoms compatible with moderate ventricular dysfunction such as fatigue and dyspnea.
Affected patients may initially respond to immunosuppressive therapy but often have clini‐
cal and histologic relapses and develop ventricular dysfunction associated with chronic in‐
flammatory changes, and mild to moderate fibrosis on histological study including giant
cells. The last form of myocarditis is chronic persistent myocarditis, which describes a group of
patients, who also present with a less distinct onset of illness, is characterized by a persistent
histological infiltrate, often with foci of myocyte necrosis but without ventricular dysfunc‐
tion, despite other cardiovascular symptoms such as chest pain or palpitation.
The previously depicted four clinicopathological forms of myocarditis are still used to describe
the clinical presentation and its progression, particularly in the absence of ongoing histological
evaluation. These categories may also provide some prognostic information and may suggest
which patients can or cannot benefit from immunosuppressive therapy. A new diagnostic cri‐
teria derived from limited data was proposed in 2009. The Lake Louise Consensus Criteria uti‐
lizes the cardiac magnetic resonance imaging (CMR) for the diagnosis of myocarditis [12].
CMR enhances the ability to detect myocardial inflammation through noninvasive means, as
well as to improve diagnostic accuracy. In these criteria, four major domains are considered
when making the diagnosis including, clinical presentation compatible with myocarditis, evi‐
dence of new or recent onset myocardial damage, increased T2 signal or delayed enhancement
on CMR (compatible with myocardial edema and inflammation), and endomyocardial biopsy
evidence of myocardial inflammation. Use of CMR appears suitable to identify patients with
significant ongoing inflammation, which may be especially important for patients with recur‐
rent or persisting symptoms and in patients with new onset heart failure. The awareness came
out that the recommendations proposed by these criteria are based on limited data and that not
all centers will be able to apply all components of the suggested protocol.
3. Clinical manifestation
The presentation of myocarditis has a wide range of clinical scenarios, from subtle to devastat‐
ing, that contributes to difficulties in the diagnosis and classification of this disorder. There are
few population-based, epidemiologic studies which have defined the presenting symptoms of
acute myocarditis; this is due to the absence of a safe and sensitive noninvasive test that can
confirm the diagnosis. Worldwide, the true frequency of disease in its less severe forms, wheth‐
er clinical or subclinical, across various age segments of the population is more difficult to ap‐
preciate. Table 1 summarizes the most significant clinical manifestations and physical findings
in patients presented with myocarditis. Typically, myocarditis has a bimodal age distribution
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in the general population, with the acute presentation more commonly seen in young children
and teenagers. In contrast, in the older adult population the presenting symptoms are more
subtle and insidious, often with dilated cardiomyopathy and heart failure. Most studies of
acute myocarditis reported a slight preponderance in male patients [13]. The male-to-female
ratio is 1.5 to 1, which may be related to a protective effect of natural hormone variations on im‐
mune responses in women [14]. The variable clinical manifestation of myocarditis in part re‐
flects the variability in histological disease severity. Myocardial inflammation may be focal or
diffuse, involving any or all cardiac chambers. Severe, diffuse myocarditis can result in a clini‐
cal manifestation of acute dilated cardiomyopathy.
Many patients with myocarditis present with a nonspecific illness characterized by fatigue,
mild dyspnea, and myalgias. Most cases of viral myocarditis are subclinical; therefore, the
patient infrequently seeks medical attention during acute illness. These subclinical cases
may have transient electrocardiographic abnormalities. The reported antecedent viral infec‐
tion syndrome is highly variable, ranging from 10 % to 80 % of patients with viral myocardi‐
tis [15-18]. Appearance of cardiac specific symptoms occurs primarily in the subacute virus
clearing phase; therefore, patients commonly present two weeks after the acute viremia. A
few patients present acutely with fulminant congestive heart failure secondary to wide‐
spread myocardial involvement. Animal models have led to a much greater understanding
of the fulminant clinical course of myocarditis, in which rapid progression, severe ventricu‐
lar dysfunction and cardiovascular collapse occurs [19]. Fulminant myocarditis, manifested
by severe hemodynamic compromise requiring high dose vasopressor support or mechani‐
cal circulatory support, was identified in 15 of 147 patients (10.2 %) in a large prospective
study [10]. Fulminant cases were additionally characterized by a distinct viral prodromal
episode, fever, and abrupt onset (generally <3 days) of advanced heart failure symptoms.
These patients typically have severe global left ventricular dysfunction and minimally in‐
creased left ventricular end diastolic dimensions. Of note, either borderline or active lym‐
phocytic myocarditis can produce this dramatic clinical presentation. The histological
features of chronic myocarditis are usually produced a more subtle clinical course. Adults
may present with heart failure years after initial index event of myocarditis.
The medical history may embrace a number of hints that merits an emphasis. Previous his‐
tory of rheumatic heart disease or symptoms defined by Jones criteria, e.g. fever or arthral‐
gia, can be a clue for the clinical diagnosis acute rheumatic fever. History of tick bite may
correlate with suspected Lyme disease. Patients treated for neoplastic disorders with chemo‐
therapeutic agents like doxorubicin may draw attention to anthracyclines-induced myocar‐
ditis. History of travel to Central or South America can be a clue for the diagnosis of Chagas
disease. Additionally, giant-cell myocarditis should be considered in patients with acute di‐
lated cardiomyopathy associated with thymoma, autoimmune disorders, ventricular tachy‐
cardia, or high-grade heart block. Furthermore, unusual cause of myocarditis, such as
cardiac sarcoidosis, should be suspected in patients who present with chronic heart failure,
dilated cardiomyopathy and new ventricular arrhythmias or second-degree or third-degree
heart block, or who do not have a response to standard care [20]. In the European Study of
the Epidemiology and Treatment of Inflammatory Heart Disease, a 3055 patients with sus‐
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pected acute or chronic myocarditis were screened, of them 72 % had dyspnea, 32 % had
chest pain, and 18 % had arrhythmias [21]. The most important clinical manifestations in pa‐
tients with myocarditis are as follows:
Clinical Manifestations
Subclinical presentation (Most cases of viral myocarditis)
Nonspecific symptoms e.g. fatigue, arthralgias andmyalgias
Clinical presentation
Shortness of breath, orthopnea or paroxysmal nocturnal dyspnea
Ankle edema
Chest pain (concomitant pericarditis)
Palpitation (arrhythmias)
Presyncope or syncope (atrioventricular block)
Sudden cardiac death (arrhythmic death)
Fever
Flu-like syndrome (e.g. pharyngitis or tonsillitis)
Thromboembolic symptoms (systemic or pulmonary)
Physical Findings
Normal or unremarkable findings
Relevant physical signs Tachypnea
Cyanosis
Elevated jugular venous pressure
Tachycardia
Signs of cardiovascular collapse and shock
Diffuse apex beat and laterally displaced (cardiomegaly)
Diminished intensity of first heart sound
Third and fourth heart sound summation gallops
Murmurs of mitral or tricuspid valves regurgitation
Pericardial friction rub and effusion (concomitant myopericarditis)
Bibasilar crackles
Hepatomegaly
Ascites
Peripheral edema
Table 1. The most significant clinical manifestations and physical findings in patient with myocarditis
Clinical Presentation
http://dx.doi.org/10.5772/54362
7
3.1. Shortness of breath
Dyspnea on exertion and fatigue are  common.  A history  of  shortness  of  breath  at  rest,
orthopnea,  ankle  edema,  or  paroxysmal  nocturnal  dyspnea  is  suggestive  of  congestive
heart failure.
3.2 Chest pain
Chest  pain  is  usually  associated  with  concomitant  pericarditis.  Chest  discomfort  is  re‐
ported  in  one  third  of  patients.  The  pain  is  most  commonly  described  as  a  pleuritic,
sharp, stabbing precordial pain. It may be substernal and squeezing and, therefore, diffi‐
cult to distinguish from that typical of ischemic pain. However, myocarditis can be mas‐
querading as  an acute coronary syndrome both clinically and on the electrocardiogram,
particularly in younger patients [22]. In one series of 34 patients with known normal cor‐
onary  anatomy  presenting  with  symptoms  and  electrocardiographic  changes  consistent
with an acute coronary syndrome, 11 (32 %) of the patients were found to have myocar‐
ditis  on  biopsy  [23].  Sarda  et  al.,  using  myocardial  indium111-labeled  antimyosin  anti‐
body and rest thallium imaging, identified 35 of 45 patients (78 %) who presented with
acute  chest  pain,  ischemic  electrocardiographic  abnormalities,  and  elevated  cardiac  bio‐
markers  as  having  diffuse  or  focal  myocarditis.  However  biopsy  verification  of  actual
myocarditis was not undertaken in this series. Complete recovery of left ventricular func‐
tion occurred at six months in 81 % of these patients [24]. Some presentations of myocar‐
ditis,  especially  those  related  to  parvovirus  B19,  present  like  an  acute  lateral  wall
myocardial  infarction.  Ischemia associated with myocarditis  may be due to localized in‐
flammation,  or  occasionally  due  to  coronary  artery  spasm  [25].  It  is  essential  for  clini‐
cians to consider acute myocarditis in younger patients who present with acute coronary
syndromes when coronary risk factors are absent,  electrocardiographic abnormalities ex‐
tend beyond a single coronary artery territory or  global  rather  than segmental  left  ven‐
tricular dysfunction is evident on echocardiography.
3.3. Palpitation, presyncope or syncope
Palpitation is a common presentation in patient with myocarditis. Presyncope or syncope in
a patient with a presentation consistent with myocarditis may be a signal for high-grade at‐
rioventricular block and risk for sudden death. Small focal inflammation in electrically sen‐
sitive areas may be the etiology of patients whose initial presentation is sudden death.
3.4. Fever
Fever with or without sweats and chills occurs in 20 % of patients presenting with myocar‐
ditis. A history of fever or flu-like syndrome in form of pharyngitis, tonsillitis, or upper res‐
piratory tract infection before admission occurs in 50 % of patients [17].
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3.5. Other symptoms
Apart from the nonspecific symptoms recognized like malaise,  myalgias and arthralgias,
other extracardiac symptoms may identify infectious, toxic agents or autoimmune diseas‐
es  affecting  the  heart  and resulting  in  a  myocarditis.  A  viral  prodrome of  fever,  myal‐
gias,  and  muscle  tenderness  may  precede  viral  myocarditis,  while  a  delayed
hypersensitivity  reaction  may be  first  apparent  from a  cutaneous  rash.  Rash,  fever,  pe‐
ripheral  eosinophilia,  or  a  temporal  relation  with  recently  initiated  medications  or  the
use  of  multiple  medications  suggest  a  possibility  of  hypersensitivity  myocarditis.  The
clinical diagnosis of myocarditis is challenging, due to its varying presentation and non‐
specific  symptoms and physical  findings.  Accordingly,  a  high level  of  clinical  suspicion
is  warranted  and  a  presumptive  diagnosis  is  usually  made  based  on  patient’s  demo‐
graphics and clinical course.
4. Physical examination
The  physical  examination  of  patient  presenting  with  myocarditis  is  frequently  normal.
Mild  cases  of  patients  with  myocarditis  may  appear  to  have  a  simple  viral  syndrome.
More  acutely  ill  patients  with  acute  myocarditis  have  the  classical  signs  of  circulatory
impairment  due to  congestive heart  failure.  Patients  may shows signs of  fluid overload
including elevated jugular venous pressure, bibasilar crackles, hepatomegaly, ascites and
peripheral  edema.  More  severe  cases  may  show  cardiovascular  collapse  and  signs  of
shock. In addition to the signs of fluid overload, physical examination may reveal direct
evidence of cardiovascular signs in symptomatic patients. Tachypnea and tachycardia are
common.  Tachycardia  is  often  out  of  proportion  to  fever.  Cyanosis  may occur  as  well.
The apex impulse may be diffuse and laterally displaced suggesting cardiomegaly. Heart
auscultation  may  reveal  diminished  intensity  of  first  heart  sound.  The  third  and  occa‐
sionally fourth heart  sound summation gallops may be noted with impaired ventricular
function, particularly when biventricular acute myocardial involvement results in system‐
ic and pulmonary congestion. If the right or left ventricular dilatation is severe, ausculta‐
tion may reveal murmurs of mitral or tricuspid valves regurgitation. Table 1 summarizes
the  most  significant  clinical  manifestations  and  physical  findings  in  patients  presenting
with myocarditis.
A pericardial  friction  rub  and effusion  may become evident  in  some patients  with  dif‐
fuse inflammation as a result of myopericarditis.  Pericardial tamponade was reported in
very  rare  occasions.  Pleural  friction  rub  may  develop  as  the  inflammatory  process  in‐
volves surrounding structures.  In cases where a dilated cardiomyopathy has developed,
signs of peripheral or pulmonary thromboembolism may be encountered. Certain physi‐
cal  findings  may  imply  a  specific  cause  of  myocarditis.  Enlarged  lymph  nodes  might
suggest  systemic sarcoidosis.  A pruritic,  maculopapular  rash may suggest  a  hypersensi‐
tivity  reaction,  often  to  a  drug  or  toxin.  Acute  rheumatic  fever  can  present  with  the
modified Jones criteria.
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5. Electrocardiogram findings
Generally, the Electrocardiogram (ECG) is a sensitive means in myocarditis. However, its
diagnostic  value  is  limited  by  the  low  specificity  and  a  wide  diversity  of  changes  ob‐
served during the  course  of  disease.  ECG must  be  timely  repeated,  since  minor  abnor‐
malities  detected  initially  may  become  subsequently  more  apparent.  ECG  findings
associated  with  myocarditis  may  include  first-,  second-  or  third-degree  atrioventricular
block,  intraventricular  conduction delay (widened QRS complex),  bundle  branch or  fas‐
cicular block, reduced R wave height, abnormal Q waves, ST-T segment changes or low
voltage.  In  one  report,  either  ST-segment  elevation or  T-wave inversion was  present  as
the most sensitive ECG criterion in <50% of patients,  even during the first weeks of the
disease [26]. A gradual increase in the width of the QRS complex may be a sign of exac‐
erbation  of  myocarditis.  Frequent  premature  beats,  supraventricular  tachycardia  and at‐
rial  fibrillation  may  arise  as  well.  Arrhythmias  such  as  sinus  arrest,  ventricular
tachycardia, ventricular fibrillation or asystole may occur and threaten the life of patients
with myocarditis. Hence, continuous ECG monitoring is crucial to detect potentially fatal
arrhythmias.
6. Clinical manifestation of complications
Despite the fact that a substantial number of myocarditis are never coming to medical atten‐
tion, a less frequent form of myocarditis is fulminant and leads rapidly to cardiovascular
collapse and shock that requires mechanical ventilation. In contrast, if these patients survive
the first 3-4 weeks of illness they have almost complete recovery and far fewer long term
complications compared with those patients with more indolent courses [27,28]. Generally,
there are a number of well recognized complications that may be encountered in the variety
of clinical scenarios of patients with myocarditis.
6.1. Congestive heart failure
In many patients who develop heart failure,  fatigue and decreased exercise capacity are
the initial manifestations. However, diffuse, severe myocarditis, if rapid in evolution, can
result  in  acute  myocardial  failure  and cardiogenic  shock.  Signs  of  right  ventricular  fail‐
ure include increased jugular venous pressure, hepatomegaly, and peripheral edema. The
decline in right ventricular function "protects" the left side of the circulation so that signs
of left  ventricular failure (such as pulmonary congestion) may not be seen.  If,  however,
there  is  predominant  left  ventricular  involvement,  the  patient  may  present  with  symp‐
toms of  pulmonary  congestion  including  dyspnea,  orthopnea,  pulmonary  crackles,  and,
in  severe  cases,  acute  pulmonary  edema.  Patients  with  persistent  viral  genome  expres‐
sion  show  limited  recovery  of  left  ventricular  function,  decreased  stroke  volume  index
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and more stiffness of the ventricle with the resultant long-term morbidity of heart failure
and a mortality of nearly 25 % [29].
6.2. Arrhythmias
A number of arrhythmias may be seen during the clinical course of myocarditis. Sinus ta‐
chycardia is more frequent than serious atrial or ventricular arrhythmias, while palpitations
secondary to premature atrial or, more often, ventricular premature complexes are common.
Ventricular arrhythmias and variable degree heart blocks are uncommon, but well recog‐
nized clinical presentations [30,31]. Persistent complex ventricular arrhythmias after appa‐
rent resolution of myocarditis were reported in children and young adults as well [32].
Several series have examined the frequency of myocarditis among patients evaluated for life
threatening ventricular arrhythmias that occurred in the absence of structural heart disease
[33-35]. These patients tend to be younger than 50 years and to have normal or near-normal
left ventricular systolic function. The frequency of syncope or cardiac arrest as reported has
ranged from 8 % to 61 % [33,34]. Biopsy evidence of myocarditis among patients without
structural heart disease has ranged from 8 % to 50 %. On the other hand, patients with ven‐
tricular arrhythmias due to lymphocytic or granulomatous myocarditis have a higher risk.
Sustained ventricular tachycardia or new heart block in the setting of rapidly progressive
congestive heart failure suggests giant cell myocarditis.
Granulomatous myocarditis has been associated more frequently with life threatening ven‐
tricular arrhythmias, syncope, and high-grade atrioventricular block requiring temporary or
permanent ventricular pacing than has lymphocytic myocarditis [36-38]. Furthermore, gran‐
ulomatous myocarditis might be suspected in patients who present with apparently chronic
dilated cardiomyopathy yet with new ventricular arrhythmias or heart block or who do not
have a response to optimal care [20].
6.3. Sudden cardiac death
The risk of sudden arrhythmic death in patients with myocarditis is increasingly appreci‐
ated in the current morbidity and mortality data. The discovery of myocarditis in 1 to 9
% of routine postmortem examinations suggests that myocarditis is a major cause of sud‐
den,  unexpected death [16].  Although heart  failure  and cardiomyopathy are  more com‐
mon  clinical  presentations,  patients  with  myocarditis  may  present  with  syncope  or
unexpected sudden cardiac death,  presumably due to ventricular tachycardia or fibrilla‐
tion  [39-42].  Myocarditis  is  a  significant  cause  of  sudden,  unexpected  death  in  adults
younger than age 40 years and elite young athletes. In these presumably healthy individ‐
uals,  autopsy findings have revealed myocarditis  in up to 20 % of  cases [43].  In an au‐
topsy series of patients under age 40 who presented with sudden death in the absence of
known heart disease, myocarditis was responsible for 22 % of cases under age 30 and 11
%  in  older  subjects  [39].  In  another  autopsy  study  of  sudden  death  occurring  in  1866
competitive athletes, myocarditis was present in 6 % of the cardiovascular deaths [44]. In
one  more  series  of  autopsies  in  military  recruits,  myocarditis  accounted  for  20  %  of
deaths due to identifiable structural cardiac abnormalities [40].
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6.4. Dilated cardiomyopathy
A substantial subset of symptomatic cases of postviral or lymphocytic myocarditis present
with a syndrome of heart failure and dilated cardiomyopathy. A clinical and pathologic syn‐
drome that is similar to dilated cardiomyopathy (DCM) may develop after resolution of vi‐
ral myocarditis in animal models and biopsy-proven myocarditis in human subjects [45].
This has led to speculation that DCM may develop in some individuals as a result of sub‐
clinical viral myocarditis. Theoretically, an episode of myocarditis could initiate a variety of
autoimmune reactions that injure the myocardium and ultimately result in the development
of DCM. These abnormalities in immune regulation and the variety of antimyocardial anti‐
bodies present in DCM are consistent with this hypothesis. Enteroviral RNA sequences may
be found in heart biopsy samples in DCM but with a very variable frequency (0–30 %),
[46,47]. Furthermore, analysis of human viruses other than enteroviruses suggests that ade‐
noviruses, herpes, and cytomegalovirus can also cause myocarditis and potentially DCM,
particularly in children and young subjects [48,49].
In most acute cases of lymphocytic myocarditis, left ventricular function improves over one
to six months with standard heart failure care. However a substantial minority will develop
a persistent inflammation that leads to chronic cardiomyopathy. In the patients who devel‐
op chronic cardiomyopathy, the risk of heart transplantation and death is high. In a large
review of 1230 cases of initially unexplained cardiomyopathy, 9 % were thought to be due to
myocarditis [50]. A similar prevalence of 10 % was noted in the Myocarditis Treatment Trial
in which endomyocardial biopsy was performed in over 2200 patients with unexplained
heart failure of less than 2 years duration [18].
6.5. Thromboembolism
Thromboembolism, arterial and venous, is more evident in patients with left ventricular
dysfunction, and appears to be quite frequent complication in certain forms of myocarditis
and cardiomyopathies. Additionally, the risk of thromboembolism from either tissue or
thrombus from the biopsy site is higher in left ventricular biopsy. Right-sided thromboemb‐
olism can be due to thrombus from the venous access sheath, particularly with the internal
jugular approach. The possibility of some small added diagnostic yield by taking biopsy
samples of the left ventricle in addition to the right is outweighed by the attendant risk of
systemic embolism.
Thromboembolism is  frequent in advanced Chagas disease,  and its  occurrence is  proba‐
bly  underestimated  [51,52].  At  autopsy,  73  %  of  patients  have  left  or  right  ventricular
mural thrombi,  with evidence of  pulmonary or systemic embolization in 60 % [53].  The
apical  aneurysm  typical  of  Chagas  disease  is  particularly  prone  to  the  formation  of
thrombi and is associated with a high incidence of thromboembolic events [54]. Further‐
more, there is a high incidence of thromboembolism in population with peripartum car‐
diomyopathy.  Thrombi  are  the  result  of  the  hypercoagulable  state  of  pregnancy and of
stasis and turbulent flow in the dilated heart. Thrombi often form in patients with lower
left ventricular ejection fraction (<35 %), [55,56]. Higher mortality rates have been report‐
ed to be due to thromboembolism as well [57].
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6.6. Recurrent myocarditis
In the majority of patients,  the clinical course of myocarditis is self-limited, and there is
complete  resolution  of  myocardial  inflammation  without  further  relapse  or  sequelae.
However, the disease has been observed to recur in a similar scenario to initial presenta‐
tion, which then may resolve spontaneously or be associated with heart failure, arrhyth‐
mias,  or death. Chronic myocarditis may be considered to be one of the mechanisms of
the process of recurrence. Recurrence was reported in 10 to 25 % of patients after appa‐
rent resolution of the initial  illness [58,59].  Recurrence of myocarditis  is  well  recognized
in patients with acute rheumatic fever. It is also demonstrated in subsequent pregnancies
after peripartum cardiomyopathy and recurrence should be suspected if ventricular func‐
tion subsequently deteriorates [59].  Women should be counseled to avoid pregnancy af‐
ter  a  diagnosis  of  peripartum  cardiomyopathy.  Recurrence  was  also  described  in  giant
cell myocarditis in transplanted heart which responded to intensive immunosuppression.
History of third time recurrences of active myocarditis proven by endomyocardial biopsy
associated with  complete  atrioventricular  block  was  described as  well  and viral  studies
showed no evidence of recent infection [60]. Another report present recurrent viral myo‐
carditis  and vaccine-associated myocarditis  in a single patient  with complete reversal  of
the  cardiomyopathy  and  return  to  normal  cardiac  function  [61].  Moreover,  some  cases
were observed to have recurrent myocarditis after tapering of immunosuppressive thera‐
py  and  previous  biopsy  specimens  showing  healed  myocarditis.  One  report  indicated
that  pericarditis  on  initial  presentation  may  be  associated  with  a  higher  rate  of  recur‐
rence of myocarditis [62]. However, in reality, there are no reliable predictors that identi‐
fy patients likely to have recurrence.
7. Manifestations of specific forms of myocarditis
Specific clinical forms of myocarditis of variable etiologies will be described below. Table 2
summarized some key clinical hints among specific forms of myocarditis that help with the
clinical diagnosis.
7.1. Viral myocarditis
Amongst the multiple infectious etiologies which have been implicated as the cause of clini‐
cally significant acute myocarditis, viral myocarditis is the most common and the enterovi‐
rus coxsackie B the most significant. Numerous seroepidemiologic and molecular studies
have linked coxsackievirus B to outbreaks of myocarditis which occurred before the 1990s.
The spectrum of viruses that were detected in endomyocardial biopsy samples shifted from
coxsackievirus B to adenovirus in the late 1990s. In the last decade a number of reports im‐
plicate new viruses in the etiology of myocarditis and dilated cardiomyopathy. The parvovi‐
rus B19 was identified in patients with myocarditis in Germany [63,5], and hepatitis C virus
was reported in Japan [64,65] as well.
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Clinical clues Clinical diagnosis Comments
Preceding upper respiratory febrile or flu-like illness
(viral nasopharyngitis or tonsillitis)
Viral myocarditis Often self-limited
Patients present with chronic heart failure,
dilated cardiomyopathy and new arrhythmias or heart
block with no response to standard care
Sarcoid
myocarditis
Enlarged lymph
nodes suggest
systemic sarcoidosis
Cutaneous rash (pruritic, maculopapular),
fever, peripheral eosinophilia or a temporal
relation with recently initiated medications or the use of
multiple medications
Hypersensitive/
eosinophilic
myocarditis
Patients treated with anti-neoplastic chemotherapeutic
agents
Anthracyclines-induced
myocarditis
History of travel to Central or South America, Systemic or
pulmonary thromboembolism
Chagas disease The apical aneurysm is typical
in advanced disease
History of residence or travel through the
endemic area; previous tick bites; prior or
current erythema migrans lesions and
coexistence of neurologic dysfunction
Lyme disease Varying degrees of
atrioventricular
conduction block is
common
Previous history of rheumatic heart disease
or symptoms defined by Jones criteria e.g.
erythema marginatum, polyarthralgia, chorea,
subcutaneous nodules fever or arthralgia
Acute rheumatic
fever
Heart failure developing in the last month
of pregnancy or within 5 months following
delivery
Peripartum
cardiomyopathy
Higher incidence of
thromboembolism
(hypercoagulable state of
pregnancy). More often
when left ventricular ejection
fraction <35 %
Sustained ventricular tachycardia in rapidly
progressive heart failure associated with
thymoma, autoimmune disorders, or high-grade
heart block
Giant-cell
myocarditis
Syncope or sudden death
develop due to ventricular
arrhythmias or heart block
Table 2. Some key clinical hints among specific forms of myocarditis that help with the clinical diagnosis.
Early studies suggested that cardiac involvement occurred in 3.5 to 5 % of patients during
outbreaks of coxsackievirus infection [66,67]. Most cases of enteroviral myocarditis or peri‐
carditis occur in children and young adults, two-thirds of whom males. In the majority of
patients, active myocarditis remains unsuspected because the subclinical and self-limited
pattern of presentation or the presence of myocarditis may be inferred only by the finding of
transient electrocardiographic ST-T-wave abnormalities. In addition, subtle cardiac symp‐
toms and signs may be overshadowed by the systemic manifestations of the underlying in‐
fection or disease process. Clinically, patients give a history of a preceding upper respiratory
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febrile illness or a flu-like syndrome, and viral nasopharyngitis or tonsillitis may be evident.
In the United States Myocarditis Treatment Trial, 89 % of subjects reported a syndrome con‐
sistent with a viral prodrome [18]. The patient may also have fever, myalgias, and muscle
tenderness, that is followed by chest pain, dyspnea or arrhythmias, and occasionally heart
failure. A pericardial friction rub is documented in half of cases, and the electrocardiogram
shows ST-segment elevation or ST- and T-wave abnormalities. Most adults recover com‐
pletely and only a minority of cases progress to chronic dilated cardiomyopathy.
In addition to the coxsackievirus B, other members of the genus Enterovirus (coxsackievirus
A, echovirus, and poliovirus) and many other viruses have also been associated, less fre‐
quently, with myocarditis; these viruses include influenza virus, Epstein–Barr virus, cyto‐
megalovirus, human herpes virus [68], and varicella-zoster virus. Myocarditis and
pericarditis were reported in association with influenza virus infection during the 1918–1919
pandemic. Unusually, myocarditis has also been described as a complication of mumps in a
severe but usually self-limited form. Molecular diagnostic assays have implicated mumps
virus in some cases of endocardial fibroelastosis following myocarditis as well. In a recent
study of 172 patients with a biopsy sample showing myocarditis, the most common viruses
were parvovirus B19, 36.6 %; enterovirus, 32.6 %; co-infection with HHV-6 and parvovirus
B19, 12.6 % human herpes virus 6 (HHV-6), 10.5 %; adenovirus, 8.1 % [63].
The novel influenza virus A (H1N1) pandemic began in Mexico in 2009 and rapidly spread
worldwide. Cardiac complications of H1N1 infection were uncommonly reported. Sudden
death as a result of myocarditis was a rare recognized complication in otherwise immuno‐
competent individuals, despite the absence of significant respiratory tract infection. A report
from Japan described 10 patients presented with fulminant myocarditis which was con‐
firmed by endomyocardial biopsy in 6 patients, 8 of the cases were rescued [68]. Also, influ‐
enza myocarditis was documented in a previously healthy adult due to 2009 pandemic
H1N1 virus [69]. Another fatal case of acute myocarditis was reported in an immunocompe‐
tent young woman; the autopsy revealed a predominantly lymphocytic myocarditis [70].
Cases diagnosed with fulminant myocarditis were also described in pediatric population,
with fatal outcomes within a 30-day of presentation [71]. Though viral myocarditis is most
often self-limited and without sequelae, fulminant condition with arrhythmias, heart failure
occurs. Arrhythmias are common and are occasionally difficult to manage. Patients with ful‐
minant myocarditis may require mechanical cardiopulmonary support or cardiac transplan‐
tation, but the majority survived and many demonstrate substantial recovery of ventricular
function. Patients with myocarditis and pulmonary hypertension are at a particularly high
risk of death. Deaths attributed to heart failure, tachyarrhythmias, and heart block has been
reported and it seems prudent to monitor the electrocardiogram of patients with arrhyth‐
mias, especially during the acute illness. In some patients, myocarditis simulates acute myo‐
cardial infarction, with chest pain, electrocardiographic changes, and elevated serum levels
of myocardial enzymes. Additionally, viral myocarditis are assumed to be the major causes
of chronic dilated cardiomyopathy, some cases of myocarditis may recur as well, however
the number of cases with acute myocarditis that progresses to chronic dilated cardiomyop‐
athy remains unknown.
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7.2. Human immunodeficiency virus (HIV) myocarditis
The human immunodeficiency virus type I (HIV-1) infection that causes the acquired im‐
munodeficiency  syndrome  (AIDS)  has  become  a  worldwide  pandemic.  Since  its  initial
description 3  decades  ago,  a  number  of  factors  have  changed,  which may have  altered
the  nature  of  cardiac  manifestation.  Notably,  survival  in  adult  with  HIV  infection  and
AIDS is now prolonged as a result of earlier detection and use of highly active antiretro‐
viral  therapy (HAART),  [72,73].  At the same time, conditions such as hypertension, dia‐
betes,  hyperlipidemia,  lipodystrophy and coronary artery  disease  appear  to  add further
comorbidity to HIV infection [74-76].  Human immunodeficiency virus myocarditis is the
most common cardiac pathologic finding at autopsy in HIV infected patients, prevalence
being as high as 70 % [77,79]. Myocarditis identified at autopsy or on endomyocardial bi‐
opsy in HIV-infected patients is most often nonspecific and manifests as focal, inflamma‐
tory lymphocytic  infiltrates  without  myocyte  necrosis.  However,  it  is  uncertain whether
the  myocarditis  so  frequently  observed  at  autopsy  is  clinically  relevant.  Myocarditis
should  be  considered  in  any  HIV-infected  patient  with  dyspnea  or  cardiomegaly.  It  is
present either with signs and symptoms of congestive heart failure, or asymptomatic left
ventricular  (LV) dysfunction at  echocardiography.  Of  note,  the  clinical  features  of  other
concomitant non-cardiac disorders may mask cardiac involvement and steer to inaccurate
approach,  since  myocardial  manifestations  due  of  HIV  infection  may  respond  at  least
transiently  to  standard therapy.  A prospective  long-term clinical  and echocardiographic
follow-up study of asymptomatic HIV-positive patients showed a mean incidence of pro‐
gression  to  dilated  cardiomyopathy  of  15.9  cases  per  1,000  patient/year.  The  precise
pathogenesis of myocarditis in AIDS is unclear. Possible direct action of HIV on myocar‐
dial tissue or an autoimmune process induced by HIV, possibly in association with other
cardiotropic viruses,  have been proposed. It  is  difficult  to assess the clinical  significance
of  viral  infection of  the myocardium in HIV infected patients.  A histologic  diagnosis  of
myocarditis was reported in 83 % of patients with dilated cardiomyopathy. This signifi‐
cant proportion had focal, nonspecific lymphocytic myocarditis [80]. Dilated cardiomyop‐
athy can be subclinical or may present with overt clinical findings. Cardiac involvement
is often subclinical as echocardiographic studies have demonstrated LV dysfunction in 41
% of asymptomatic HIV-positive individuals [81].  However,  in the primary care setting,
AIDS  cardiac  complications  are  unusual.  One  autopsy  series  demonstrated  no  cardiac
disease in 115 consecutive autopsies of patients who died of AIDS-related complications
[79]. In one series of 416 HIV-positive patients from Rwanda without previous history of
cardiovascular disease and not receiving HAART an echocardiographically evident dilat‐
ed cardiomyopathy was found in 17.7 % [82]. Overt clinical involvement is seen in 10 %
of HIV patients,  and the most  common clinically  significant  finding is  a  dilated cardio‐
myopathy associated with typical findings of congestive heart failure, namely edema and
shortness  of  breath.  Apart  from  clinical  manifestations  which  may  be  a  direct  conse‐
quence of HIV infection, there may be consequence of possible etiologies related to non-
HIV  cardiotrophic  viral  infection,  postviral  autoimmune  mechanism,  drug  toxicity,  or
neoplastic infiltration by Kaposi sarcoma or lymphoma.
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Since the introduction of HAART regimens there has been a marked reduction in the inci‐
dence of myocarditis and opportunistic infections, which has led to a nearly 30 percent re‐
duction in HIV-associated cardiomyopathy [83]. Opportunistic infections including bacteria,
fungi, protozoa, and viruses are the most frequent cause of morbidity and mortality in
AIDS, in 10 to 15 % of cases [84]. However, symptomatic disease appears to be rare. Toxo‐
plasma gondii is the most frequently documented infectious cause of myocarditis associated
with AIDS. Myocardial toxoplasmosis has been described in 1 to 16 % of autopsy series of
patients dying of AIDS [77,78,85]. Cytomegalovirus is another common opportunistic infec‐
tion in patients with late stage AIDS that can cause myocarditis [83,86]. Other virus identi‐
fied within the myocardium of HIV-infected or AIDS patients, either at antemortem
endomyocardial biopsy or from autopsy material, include Epstein-Barr and coxsackie B vi‐
rus in adults [80,87,88]. These viruses may be present as either primary infection or as coin‐
fection, and can occur with or without associated myocarditis and with or without
associated LV dysfunction. Other infections, like myocardial tuberculosis, appears to be rare
[89]. Fungal myocarditis is another unusual complication of disseminated infection that is
identified most often at autopsy. Various fungal organisms have been identified in the myo‐
cardium at autopsy with associated myocarditis. Cardiac cryptococcus has been diagnosed
in association with congestive heart failure and resolved after therapy [90-92].
Other possible etiologies of LV dysfunction are drug toxicity from either abuse of illicit sub‐
stances, or iatrogenic disease from agents used in the therapy of AIDS. Alcohol, cocaine, or
heroin may contribute to LV dysfunction in many cases [93-95]. Therapeutic agents implicat‐
ed as potential cardiac toxins include zidovudine [96,97], interleukin-2 [98], and interferon
alfa-2 [99,100]. Neoplastic infiltration of the heart by Kaposi sarcoma is frequently seen at
autopsy and usually associated with widespread disease in the terminal phases of AIDS
[101]. Non-Hodgkin lymphoma is also observed in this setting and also associated with
widespread disease [102].
7.3. Bacterial myocarditis
Nowadays, myocarditis of infectious etiology caused by non-viral agents is less frequent
worldwide. Bacterial involvement of the heart is uncommon, but when it does occur, it is
usually as a complication of endocarditis. Various bacteria include (Corynebacterium diphther‐
iae, Streptococcus pyogenes, Staphylococcus aureus, Haemophilus pneumoniae, Salmonella spp.,
Neisseria gonorrhoeae, Leptospira, Borrelia burgdorferi, Treponema pallidum, Brucella, Mycobacteri‐
um tuberculosis, Actinomyces, Chlamydia spp., Coxiella brunetti, Mycoplasma pneumoniae and
Rickettsia spp). Bacteria like streptococcal and staphylococcal species and Bartonella, Brucella,
Leptospira, and Salmonella species can spread to the myocardium as a consequence of severe
cases of endocarditis. Some forms of bacterial myocarditis will be discussed below.
7.3.1. Diphtheritic myocarditis
Worldwide, the most common bacterial cause of myocarditis is diphtheria. As early as 1806,
a relationship between infection (diphtheria) and chronic heart disease was postulated, but
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it was not until the 1970s, with the advent of endomyocardial biopsy, that the diagnosis of
myocarditis could be established during life.
The risk of developing cardiac toxicity is proportional to the severity of local infection. Cory‐
nebacterium diphtheriae produce toxins that inhibit protein synthesis that can cause myocardi‐
tis and lead to a dilated, flabby, hypocontractile heart. The manifestations of diphtheritic
myocarditis include various arrhythmias, conduction disturbances, and dilated cardiomyop‐
athy. Cardiomegaly and severe congestive heart failure typically appear after the first week
of illness. However, clinically evident cardiac manifestations like dyspnea, muffled heart
sounds, gallop rhythm or cardiac dilatation are much less common, occurring in 10 to 25 %
of all patients with diphtheria [103]. Myocarditis occurred in 22 % of 656 hospitalized pa‐
tients with diphtheria in the Kyrgyz Republic in 1995; 7 % of patients with myocarditis and
2 % of patients without myocarditis died [104]. Myocarditis as evidenced by electrocardio‐
graphic changes such as ST-T wave changes, QTc prolongation, and/or first-degree heart
block can be detected in as many as two-thirds of cases, often occurring when local respira‐
tory symptoms are improving [105,106]. The conduction system is frequently involved.
Complete heart block from diphtheritic myocarditis was almost always fatal before tempo‐
rary cardiac pacemakers were developed. Diphtheritic myocarditis is considered the most
serious complication and remains the major cause of mortality [107]. The death rate is high‐
est during the first week of illness, particularly among patients with bull-neck diphtheria
and among patients with myocarditis who develop ventricular tachycardia, atrial fibrilla‐
tion, or complete heart block.
7.3.2. Lyme myocarditis
Lyme disease is an inflammatory disease caused by infection with the spirochete Borrelia
burgdorferi. In United States, carditis occurs in approximately 5 % of infected patients, while
it is less frequent in Europe, affecting approximately 0.3 to 4.0 % of untreated adults [108].
This difference may be related to infection by different organisms. A careful history should
address risk factors or possible evidence of B. burgdorferi infection particularly in the pres‐
ence of atrioventricular conduction abnormalities [109]. These include history of residence
or travel through an endemic area; previous tick bites; prior or current erythema migrans
lesions and coexistence of neurologic dysfunction compatible with neurologic Lyme disease.
Cardiac Lyme disease occurs during the early disseminated phase of the disease, usually
within weeks to a few months after infection [110]. In a patient with suspected Lyme disease
after a tick bite, the possibility of coinfection with Ehrlichia (ehrilichiosis) and Babesia (babe‐
siosis) should be considered as both can also cause myocarditis.
There is a male predominance of approximately 3:1 in cardiac Lyme disease [111]. Patients
with cardiac involvement may be asymptomatic and clinically unapparent. However, some
patients develop symptomatic myocarditis with cardiac muscle dysfunction and/or associat‐
ed pericarditis [112,113]. Symptoms mainly include palpitations, shortness of breath, chest
pain, presyncope or syncope. In a review of 84 patients with Lyme carditis, the United States
Centers for Disease Control and Prevention reported palpitations in 69 %, conduction abnor‐
malities in 19 %, myocarditis in 10 % and left ventricular failure 5 % [114]. Endomyocardial
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biopsy samples resemble idiopathic lymphocytic myocarditis, and rarely the spirochetal or‐
ganisms are identified [108,109,115]. Atrioventricular conduction block of varying degrees
are the most common manifestation of Lyme carditis. In some patients, heart block is the
first and only manifestation of Lyme disease [116]. Patients may present with first-degree
heart block, which can progress to second-degree or complete heart block over a short peri‐
od of time [117]. One review of 52 patients with Lyme carditis found that 87 % had atrioven‐
tricular block, which was usually symptomatic [109]. Wenckebach periodicity occurred in 40
% and complete atrioventricular block in 50 %; other findings include bundle branch and
fascicular blocks, although rare. In another report, 38 % of patients with Lyme carditis re‐
quired a temporary pacemaker [118]. Patients with a PR interval greater than 300 millisec‐
onds carry a highest risk for progression to complete heart block, which may develop
rapidly [119]. Complete heart block caused by Lyme disease typically resolves within one
week, and minor conduction disturbances within six weeks [109,110]. Other reports showed
heart block usually persisting for 3 to 42 days, often resolving spontaneously [108,119-121].
In Europe, scattered case reports have suggested that B. burgdorferi may, in isolated cases, be
a cause of chronic cardiomyopathy [122,123]. This has not been shown in the United States.
A small Dutch series evaluated 42 patients with dilated cardiomyopathy [112]. Nine were
seropositive for anti-B. burgdorferi; six recovered fully, two had a partial response, and one
showed no improvement.
7.3.3. Salmonella myocarditis
Typhoid fever is a life-threatening illness rarely complicated by myocarditis. Salmonella my‐
ocarditis may produce variable clinical manifestations from latent to severe clinical forms,
such as acute congestive heart failure or sudden cardiac death [124,125]. Postmortem studies
suggest that myocarditis is a major cause of sudden unexpected death in young adults and
may account for 20 % of cases [16].
7.3.4. Yersinia myocarditis
Myocarditis sometimes occurs as a complication of Yersinia. Clinical evidence of Campylo‐
bacter-associated myocarditis described in association with Campylobacter spp. Enteritis
[126]. Mild, self-limited myocarditis accompanies 10 % of cases of Yersinia-induced arthritis
and can occur independently. Typical manifestations include cardiac murmurs and transient
electrocardiographic abnormalities, such as prolongation of the PR interval and nonspecific
ST-segment and T wave changes. The syndrome of Yersinia-induced arthritis and carditis
can be confused with acute rheumatic fever.
7.3.5. Legionella myocarditis
Myocardial involvement is a rare manifestation of Legionella infection, although the most
common extrapulmonary site of Legionnaires’ disease is the heart. Numerous reports have
described myocarditis, pericarditis, postcardiotomy syndrome, and prosthetic valve endo‐
carditis [127-129]. Most cases have been hospital acquired. Legionella carditis in the adult
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population is invariably seen in association with pneumonia; however, isolated Legionella
myocardial involvement without associated pneumonia has been reported [130].
7.3.6. Mycoplasma myocarditis
Cardiac abnormalities have rarely been reported in conjunction with Mycoplasma pneumoniae
infection, including myocarditis and pericarditis [131,132]. Myocarditis has been described
in rare autopsy reports as well. Cardiac manifestations include rhythm disturbances, con‐
gestive heart failure, chest pain, and conduction abnormalities on the electrocardiogram.
7.3.7. Q fever myocarditis
Myocarditis, though uncommon, may be a particularly severe manifestation of Q fever. In a
study of 1070 patients with acute Q fever from southern France, 1 % had pericarditis, and 1
% had myocarditis. In other series of 1276 patients with Q fever over a 15-year period, only
eight developed myocarditis but two were among the only 12 patients with Q fever who
died [133]. Q fever may also cause endocarditis which usually occurs in patients with previ‐
ous valvular damage or immunocompromise particularly on a bicuspid aortic valve or a
prosthetic valve.
7.3.8. Chlamydial myocarditis
Chlamydial infection also has been reported in association with clinical manifestations of
myocarditis [134].
7.3.9. Relapsing fever myocarditis
Relapsing fever is an arthropod-borne infection characterized by recurrent episodes of fever,
caused by spirochetes of the genus Borrelia. The first episode of illness tends to be the most
severe. Myocarditis appears to be common in both louse-borne and tick-borne relapsing fe‐
ver. Clinical and electrocardiographic evidence of myocarditis and myocardial dysfunction
includes a prolonged QTc interval, commonly a galloping third heart sound, elevated cen‐
tral venous pressure, arterial hypotension, and rarely pulmonary congestion. Heart involve‐
ment has been prominent in fatal cases [135].
7.4. Acute rheumatic fever
Acute rheumatic fever (ARF) is a nonsuppurative complication of group A streptococcus
pharyngitis that occurs two to four weeks following infection and arises as an autoimmune
response to extracellular or somatic bacterial antigens that share epitopes similar to human
tissue. Rheumatic fever remains one of the most important cardiovascular diseases that
cause significant cardiac morbidity and mortality in developing countries [136]. In devel‐
oped countries, ARF is generally preceded by pharyngitis but not skin infection [137]. How‐
ever, data from endemic regions with ARF and rheumatic heart disease suggest a less clear
association [138-140]. Acute rheumatic fever occurs most frequently in children 5 to 15 years
of age. The incidence of rheumatic heart disease in patients with a history of ARF is variable;
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in general, valvular damage manifesting as a murmur later in life is likely to occur in about
50 % of patients with evidence of carditis at initial presentation [141,142]. The myocardial
lesions consist of nonspecific lymphocytic myocarditis and Aschoff nodules. The latter are
pathognomonic of ARF. Myocarditis is often indicated by cardiomegaly and/or congestive
heart failure (CHF), particularly in the absence of a significant pericardial effusion. The pres‐
ence of valvulitis is established clinically by auscultatory findings. Although CHF in rheu‐
matic fever patients traditionally has been ascribed to severe myocardial inflammation,
endomycardial biopsy in patients with rheumatic carditis does not show significant evi‐
dence of myocyte damage [143]. In addition, echocardiographic left ventricular ejection frac‐
tion and indices of myocardial contractility remain normal in patients with rheumatic
carditis even in the presence of CHF [144]. Further, CHF occurs only in the presence of he‐
modynamically significant valvular lesions. The diagnosis of ARF is established largely on
clinical grounds. The clinical manifestations were initially described by Jones [145]. Subse‐
quently, guidelines for the diagnosis of rheumatic fever reviewed have been established by
the American Heart Association Working Group in 2002 [146]. The five major manifestations
include migratory arthritis, carditis and valvulitis, central nervous system involvement (e.g.,
Sydenham chorea), erythema marginatum and subcutaneous nodules. Whereas the four mi‐
nor manifestations include, arthralgia, fever, elevated acute phase reactants (erythrocyte
sedimentation rate, C-reactive protein) and prolonged PR interval. The probability of ARF is
high in the setting of group A streptococcal infection followed by two major manifestations
or one major and two minor manifestations. Strict adherence to the Jones criteria in areas of
high prevalence may result in under detection of the disease. This was illustrated in a report
of 555 cases of confirmed ARF among Australian aboriginals in whom monoarthritis and
low-grade fever were important manifestations [147].
7.5. Chagas myocarditis
Chagas disease is a protozoan infection due to Trypanosoma cruzi; transmitted by an insect
vector, produces an extensive myocarditis that typically becomes evident years after the ini‐
tial infection. It is a major public health problem in endemic areas and in immigrants from
rural Central or South America. Chagas myocarditis is by far the most common form of car‐
diomyopathy in Latin American countries [148]. Chagas disease consists of acute and chron‐
ic phases. During the chronic phase, many patients present the indeterminate form. The
latter describes patients who have positive serology, but no symptoms, physical signs, or
laboratory evidence of organ involvement [149].
7.5.1. Acute phase
The first signs of acute Chagas’ disease develop at least 1 week after contact with the infect‐
ed vector. Local skin indurated erythema and swelling produces the typical portal of entry
lesions at the skin known as chagomas accompanied by local lymphadenopathy. The con‐
junctiva portal of entry may result in a unilateral painless periorbital edema and swelling of
the palpebrae (Romana's sign). Infection can also occur through blood transfusion, congeni‐
tal transmission, and, much less often, organ transplantation, laboratory accident, breast
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feeding, and oral contamination [150]. Although heart transplantation for Chagas cardiomy‐
opathy has been successfully performed, reactivation of Trypanosoma cruzi is common. These
initial local signs may be followed by malaise, fever sweating, myalgias anorexia; a morbilli‐
form rash may also appear. Generalized lymphadenopathy and hepatosplenomegaly may
develop. Cardiac failure occurs secondary to myocarditis; cardiac involvement is present in
over 90 % of those in whom the diagnosis is made [151]. The frequency and severity of myo‐
carditis are inversely proportional to age [152]. The acute symptoms resolve spontaneously
in virtually all patients, who then enter the asymptomatic or indeterminate phase of chronic
T. cruzi infection. The electrocardiogram normalizes in over 90 % of patients after one year.
The indeterminate form usually lasts 10 to 30 years and only approximately 30 % of the pa‐
tients develop overt cardiac disease. Most patients remain asymptomatic throughout their
life. The natural history of this phase of disease is characterized by subtle degree of cardiac
involvement and gradual appearance of clinical or electrocardiographic markers of cardiac
involvement, which signals the onset of the chronic phase. In one review, progression from
indeterminate to the full-blown clinical form in the chronic phase occurred at approximately
2 % per year [149]. In another report, 38.3 % of patients with positive serology but without
symptoms developed chagasic cardiomyopathy over a 10-year period [153]. About 50 % of
patients remain with the indeterminate form indefinitely [154].
7.5.2. Chronic phase
The  chronic  form  is  characterized  by  dilatation  of  cardiac  chambers,  fibrosis  and  thin‐
ning of the ventricular wall, aneurysm formation (especially at the left ventricular apex),
and mural thrombi.
Chronic progressive heart failure is the rule and is associated with poor survival. Mortal‐
ity associated with the chronic phase is almost exclusively due to cardiovascular involve‐
ment. The cause of death is sudden cardiac death in 55 to 65 %, progressive heart failure
in 25 to 30 %, and stroke in 10 to 15 % [155]. Symptoms and physical signs at this stage
of  the  disease  arise  from three  basic  syndromes  that  often  coexist  in  the  same patient,
heart  failure,  cardiac  dysrhythmia,  and  thromboembolism  (systemic  and  pulmonary).
Heart  failure  in  Chagas  heart  disease  is  usually  biventricular  and  commonly  presents
with  fatigue.  However,  right-sided  failure  manifested  with  increased  jugular  venous
pressure,  peripheral  edema,  ascites,  and  hepatomegaly  is  characteristically  more  pro‐
nounced than left-sided failure manifested with dyspnea and pulmonary rales. Both sys‐
tolic  and  diastolic  dysfunction  can  occur  [156].  Cardiac  examination  typically  reveals
murmurs of mitral and tricuspid regurgitation, wide splitting of the second heart sound
due to right bundle branch block and prominent diffuse apical thrust.
Cardiac arrhythmias may cause palpitation, lightheadedness, dizziness, or syncope. Auto‐
nomic dysfunction results in marked abnormalities in heart rate variability. Chest pain is a
common symptom and usually atypical in Chagas heart disease. It may mimic angina due to
abnormal coronary vasomotion postulated as underlying mechanism [157]. Sudden cardiac
death accounts for 55 to 65 % of deaths in CD; the real frequency of this complication is
probably underestimated, particularly in rural areas [155]. Sudden cardiac arrest can occur
Diagnosis and Treatment of Myocarditis22
even in previously asymptomatic patients [158]. However, most patients have severe under‐
lying heart disease, including ventricular aneurysms at multiple sites (posterior-lateral, infe‐
rior basal, or apical), which is a characteristic finding in Chagas heart disease [158]. Sudden
death is usually precipitated by exercise, and can be caused by VT or fibrillation, asystole, or
complete AV block [159]. The electrocardiogram is abnormal in most patients with cardiac
involvement and typically shows right bundle branch block, left anterior hemiblock and dif‐
fuse ST-T changes, which may progress to complete atrioventricular block. Ventricular ar‐
rhythmia may also be seen as premature beats that may be multiform and runs of
nonsustained ventricular tachycardia. The severity of ventricular arrhythmias tends to cor‐
relate with the degree of LV dysfunction. Other changes, like abnormal Q waves, various
degrees of atrioventricular block, QT interval prolongation and variation in the QT interval
(QT dispersion) are frequent findings [160].Virtually all types of atrial and ventricular ar‐
rhythmias can occur; atrial fibrillation and low QRS voltage may be observed in advanced
disease. A potentially serious complication of chronic Chagas heart disease is thromboembo‐
lism. In a review of 1345 autopsies, cardiac thrombus or thromboemboli were reported in 44
%; both right and left cardiac chambers being equally affected [52]. Although thromboem‐
bolic phenomena were more common in the systemic circulation, pulmonary embolism ac‐
counted for 14 % of deaths. Cardioembolism appears to be an important cause of acute
ischemic stroke. One series of 94 patients with Chagas disease in Brazil reported higher rate
of cardioembolism (56 versus 9 %) as compared to control group [161]. Stroke was also re‐
ported significantly more frequently in patients who had Chagas disease related cardiomy‐
opathy compared with patients who had other cardiomyopathies (15.0 versus 6.3 %), [162].
Echocardiography or contrast ventriculography may reveal left ventricular apical aneurysm,
regional wall motion abnormalities, or diffuse cardiomyopathy. The cause of death is either
intractable CHF or arrhythmias, with a minority of patients dying from embolic phenomena.
7.6. Fungal myocarditis
The incidence of invasive fungal disease has dramatically increased over the past few deca‐
des corresponding to the rising number of immunocompromised patients. Cardiac fungal
infection, especially myocarditis, may be difficult to recognize clinically and may in itself
produce a fatal outcome. Myocardial involvement frequently occurs in disseminated fungal
infection in which multiple organs are often affected. Conditions that appear predisposing
to fungal infection are human immunodeficiency virus infection, medication like, corticoste‐
roids, antineoplastic agents or broad-spectrum antibiotics, alone or in combination with in‐
vasive medical procedures [163]. Candida was the most frequently observed organism,
while Aspergillus was the second most frequent fungus to involve the heart. Rarely Crypto‐
coccus is identified as a cause of myocarditis as well.
7.7. Eosinophilic and hypersensitivity myocarditis
The association between eosinophilia (eosinophil count >500/mm3) and heart disease was
first  identified  by  Loeffler  [164].  A  specific  eosinophilic  form  of  myocarditis  has  been
identified  following  drug-induced  hypersensitivity  reactions  and  systemic  hypereosino‐
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philic syndromes [165]. Eosinophilic myocarditis is characterized by a predominantly ma‐
ture  eosinophils  infiltration  of  the  myocardium  and  other  organ  systems.  It  occurs  in
association  with  systemic  diseases  such  as  hypereosinophilic  syndrome,  Churg-Strauss
syndrome  and  Löffler’s  endomyocardial  fibrosis.  It  may  also  occur  in  association  with
cancer,  parasitic,  helminthic or protozoal infections such as Chagas disease,  toxoplasmo‐
sis, schistosomiasis, trichinosis, hyatid cysts and visceral larval migrans [166-168]. Eosino‐
philic  myocarditis  has  been  reported  after  vaccination  for  several  diseases,  including
smallpox [169,170].  Acute  eosinophilic  necrotizing myocarditis  is  a  rare  aggressive form
of eosinophilic myocarditis and may represent an extreme form of hypersensitivity myo‐
carditis which is characterized by acute onset, and rapidly results in cardiovascular dete‐
rioration  and  circulatory  collapse  carrying  high  mortality  rates  [171].  The  clinical
manifestations  of  eosinophilic  myocarditis  may  include  right  and  left  congestive  heart
failure, endocardial and valvular fibrosis leading to regurgitation, and formation of endo‐
cardial  thrombi.  Clinical  awareness  is  warranted  when  presentation  may  mimics  acute
myocardial  infarction,  with ischemic chest  pain and ST-segment elevation on electrocar‐
diography [172].  Hypersensitivity  myocarditis  is  a  form of  eosinophilic  myocarditis  due
to  autoimmune  reaction  affecting  the  heart  muscle,  often  induced  by  drugs.  It  is  often
first discovered at postmortem examination. In one series, the prevalence of clinically un‐
detected hypersensitivity  myocarditis  in  explanted hearts  ranged from 2.4  to  7  % [173].
Numerous drugs have been implicated in hypersensitivity myocarditis,  including antibi‐
otics,  [174]  like  penicillins,  cephalosporins  and  sulfonamides;  antipsychotics,  [175]  like
clozapine and tricyclic antidepressants [174,176,177]; other drugs like methyldopa, hydro‐
chlorothiazide, furosemide, tetracycline, azithromycin, aminophylline, phenytoin and ben‐
zodiazepines [165,178,179]. Hypersensitivity myocarditis not always develops early in the
course of medication. Patients taking the antipsychotic agent clozapine have been report‐
ed  to  develop  myocarditis  more  than  two  years  after  the  drug  was  started  [180].  Pro‐
longed continuous infusion of dobutamine has also been associated with hypersensitivity
myocarditis  which  has  been reported in  2.4  to  23  % [181,182].  Cocaine  also  rarely  pro‐
duce  a  hypersensitivity  myocarditis,  unlike  the  hypereosinophilic  syndrome,  peripheral
eosinophilia is typically absent [183].
Clinically, the presentation is often heralded by fever, peripheral eosinophilia and a drug
rash that occurs days to weeks after administration of a previously well-tolerated agent.
Electrocardiographic abnormalities show nonspecific ST segment changes or infarct patterns
[184]. Myocardial involvement varies but usually does not result in fulminant heart failure
or hemodynamic collapse. However, some patients present with sudden death or rapidly
progressive heart failure [172,174].
Eosinophilic myocarditis can be a manifestation of eosinophilia-myalgia syndrome, which is
a multisystem disease, caused by ingestion of contaminants in L-tryptophan containing
products [185], characterized by peripheral eosinophilia and generalized disabling myalgias
[186]. Eosinophils, lymphocytes, macrophages, and fibroblasts accumulate in the affected
tissues, but their role in pathogenesis is unclear. The disease is frequently evolves into a
chronic course but can be fatal in up to 5% of patients.
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7.8. Giant cell myocarditis
Idiopathic giant cell myocarditis is a rare inflammatory disease that often affects previously
healthy young adults and is frequently a fatal type of myocarditis [187]. The pathogenesis of
this disorder is not known. It is identified by the presence of multinucleated giant cells asso‐
ciated with eosinophils and myocyte destruction in the absence of granulomas on endomyo‐
cardial biopsy. It is thought to be primarily autoimmune in nature because of the reported
comorbidity with a variety of autoimmune disorders [188], thymoma [189], and drug hyper‐
sensitivity [190]. Idiopathic giant cell myocarditis is usually a fulminant form of myocardi‐
tis, characterised by a history of rapid progression of severe heart failure associated with
refractory sustained ventricular arrhythmias. Giant-cell myocarditis is sometimes distin‐
guished from the much more common postviral myocarditis by the presence of ventricular
tachycardia, heart block, and a downhill clinical course, despite optimal clinical care. In the
series of 63 patients with giant cell myocarditis enrolled in the multicenter Giant Cell Myo‐
carditis Treatment Trial, 75 % identified with heart failure symptoms as the primary presen‐
tation, 14 % with ventricular arrhythmia and heart block in 5 % [188]. Most patients will
require cardiac transplantation, the median survival from the onset of symptoms is less than
6 months and has an 89 % rate of death or transplantation. This represents a significantly
worse outcome compared to lymphocytic or viral myocarditis. Despite a 25 % incidence of
post-transplantation recurrence of giant cell myocarditis detected by biopsy, the 5-year sur‐
vival after transplantation is about 71 % which is comparable to survival after transplanta‐
tion for cardiomyopathy.
7.9. Systemic lupus erythematosus myocarditis
Acute myocarditis is an uncommon manifestation of systemic lupus erythematosus (SLE),
with a prevalence of 8 to 25 % in different studies [191,192]. Myocarditis is frequently
asymptomatic but less often may accompany other manifestations of acute SLE. In particu‐
lar, pericarditis commonly occurs in about two-thirds of patients, and generally follows a
benign course; however, pericardial tamponade or constriction occur infrequently. Myocar‐
ditis generally parallels the activity of the disease and, although common histologically,
rarely results in clinical heart failure unless associated with hypertension. African American
ethnicity is associated with a higher risk of myocarditis compared with Hispanic and Cauca‐
sian ethnicity [191]. Myocarditis should be suspected if there is resting tachycardia dispro‐
portionate to body temperature, ST and T wave electrocardiographic abnormalities and
unexplained cardiomegaly. The cardiomegaly may be associated with symptoms and signs
of heart failure, conduction abnormalities or arrhythmias [193]. Patients with SLE are at in‐
creased risk for myocardial ischemia due to accelerated atherosclerosis or coronary arteritis.
Endocardial involvement with fibrinous endocarditis [194] is another serious manifestation
that can lead to valvular insufficiencies or embolic events. Likewise, patients with the anti‐
phospholipid syndrome have a higher incidence of valvular disease, a variety of thrombotic
disorders, myocardial infarction, pulmonary hypertension, and cardiomyopathy. Myocar‐
dial biopsy reveals mononuclear cells infiltration distinguishing active myocarditis from fib‐
rosis and other causes of cardiomyopathy [195] or rarely cardiotoxicity induced by
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hydroxychloroquine [196]. Inflammation may lead to fibrosis that may be manifested clini‐
cally as dilated cardiomyopathy.
7.10. Sarcoid myocarditis
It is a granulomatous form of myocarditis. The clinical evidence of myocardial involvement
is present in approximately 5 % of patients with sarcoidosis. However, an autopsy series re‐
ported higher rates of about 25 % of subclinical cardiac involvement [197-199]. The clinical
manifestations of cardiac sarcoidosis are largely nonspecific and may precede, follow, or oc‐
cur concurrently with involvement of other organs. Sarcoid heart disease should be consid‐
ered in the evaluation of an otherwise healthy young or middle aged person with cardiac
symptoms or in a patient with known sarcoidosis who develops arrhythmias, conduction
disease, or heart failure. Patients who present with apparently chronic dilated cardiomyop‐
athy yet with new ventricular arrhythmias or second-degree or third degree heart block or
who do not have a response to optimal care are more likely to have cardiac sarcoidosis [20].
Cardiac symptoms were reported in 101 patients, when cardiac sarcoidosis was diagnosed
in 84 % compared to 4 % in asymptomatic patients [200]. Endomyocardial biopsy shows
characteristic noncaseating granulomas. However, the diagnosis can also be inferred if there
is a tissue diagnosis of sarcoidosis from an extracardiac source in the presence of a cardio‐
myopathy of unknown origin.
Electrocardiographic abnormalities are found in nearly 70 % of patients with sarcoidosis
[197]. Cardiac involvement with sarcoidosis may produce clinical symptoms and electrocar‐
diographic findings simulating myocardial infarction. Conduction abnormalities in form of
first-degree heart block due to disease of the atrioventricular node or bundle of His, and var‐
ious types of intraventricular conduction defects, are common among patients with cardiac
sarcoidosis [197]. These lesions may initially be silent, but can progress to complete heart
block and cause syncope [201]. Sustained or nonsustained ventricular tachycardia and ven‐
tricular premature beats are the second most common presentation of cardiac sarcoidosis;
electrocardiography reveals ventricular arrhythmias in as many as 22 % of patients with sar‐
coidosis [202]. Supraventricular arrhythmias are infrequent. Sudden death due to ventricu‐
lar tachyarrhythmias or conduction block accounts for 25 to 65 % of deaths due to cardiac
sarcoidosis, however, sudden death can occur in the absence of a previous cardiac event
[203-205]. Both systolic and diastolic heart failure can occur. Left ventricular aneurysms de‐
velop in patients with extensive involvement of the myocardium. Mitral incompetence may
occur with cardiac sarcoidosis due to associated systolic dysfunction and left ventricular di‐
lation or due to papillary muscle involvement by sarcoid granulomas [206]. Tricuspid regur‐
gitation with atrioventricular block secondary to infiltration of tricuspid valves and
conduction system by sarcoid granulomas has been reported as well [207]. A left atrial gran‐
ulomatous mass resembling myxoma has been reported too [208].
7.11. Peripartum cardiomyopathy
The syndrome is a rare disorder of pregnancy. It was recognized in 1937, as a distinct clini‐
cal entity [209]. Currently, the etiology of peripartum cardiomyopathy (PPCM) remains un‐
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clear. However, there is compelling data from animal and human studies suggesting that
PPCM is actually a type of myocarditis arising from an infectious, autoimmune, or idiopath‐
ic etiology. The relationship between pregnancy and viral myocarditis was first published in
1968 [210]. Endomyocardial biopsies in women with PPCM have demonstrated myocarditis
in many patients. The highest incidence of myocarditis reported in PPCM was 76 % [211],
however much lower incidence was reported (8.8 %), which found to be comparable to an
age and sex matched control population undergoing transplantation for idiopathic dilated
cardiomyopathy (9.1 %), [212]. Viral genomes of parvovirus B19, human herpes virus 6, Ep‐
stein–Barr virus and human cytomegalovirus revealed in endomyocardial biopsy specimens
from patients with PPCM [213]. Other reported data linked with Chlamydial infection [214].
Women present with heart failure during the peripartum period and become manifested in
the last month of pregnancy or within 5 months of the delivery without apparent etiology
for the heart failure can be found. The clinical scenario is challenging because many normal
women in the last month of a normal pregnancy experience dyspnea, fatigue and ankle ede‐
ma, symptoms that can mimic early congestive cardiac failure. Physical examination can be
significant for signs of right and left heart failure. Symptoms and signs that should raise the
suspicion of heart failure include paroxysmal nocturnal dyspnea, chest pain, nocturnal
cough, new regurgitant murmurs, pulmonary rales, elevated jugular venous pressure and
hepatomegaly. The electrocardiogram usually demonstrates normal sinus or sinus tachycar‐
dia rhythm, but frequent ectopy and other atrial arrhythmias may also be present. Left ven‐
tricular hypertrophy, inverted T waves, Q waves, and nonspecific ST-T changes have also
been reported [215]. Recurrence in a subsequent pregnancy has been reported. However,
significant improvement occurs in up to 50 % of affected women; others are left with a pro‐
gressive dilated cardiomyopathy.
8. Conclusion
Myocarditis presents with a highly variable clinical scenarios. A thorough medical history
with emphasis on possible causes is essential. A scrupulous awareness to ample clinical sce‐
narios is essential for clinicians, particularly when the cases are lacking apparent etiologies,
or the presentations resembles that of acute myocardial infarction, asymptomatic left ven‐
tricular systolic dysfunction, unexplained ventricular tachyarrhythmias or cardiogenic
shock. Clinicians need to be attentive when evidence is present of myocardial injury not at‐
tributable to epicardial coronary artery disease, primary valvular disease or noninflammato‐
ry causes. Usually, most cases of myocarditis are self-limited and spontaneous improvement
occurs in a substantial number of patients with lymphocytic disease but is rarely, if ever, ob‐
served with granulomatous myocarditis. While routine diagnostic endomyocardial biopsy is
not required in most cases of suspected acute myocarditis, the need for biopsy will depend
upon the time course and severity of the clinical presentation.
Better understanding of the clinicopathological that characterize the diverse clinical scenar‐
ios and more comprehensive understanding of the natural history of the various subtypes of
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myocarditis should assist clinicians for better approach and subsequently plan more effec‐
tive therapy in the future.
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